These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 29560564

  • 1. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC, Bastos AU, da Costa VR, Delcelo R, Lindsey SC, Colozza-Gama GA, Peng H, Rauscher FJ, Oler G, Cerutti JM.
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [Abstract] [Full Text] [Related]

  • 2. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J, Yang Y, Zhao J, Shi L, Xu Y, Yu K, Guo C.
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [Abstract] [Full Text] [Related]

  • 3. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [Abstract] [Full Text] [Related]

  • 4. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia.
    Zhou D, Li Z, Bai X.
    Med Sci Monit; 2018 Sep 26; 24():6795-6808. PubMed ID: 30254191
    [Abstract] [Full Text] [Related]

  • 5. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H, Li W, Yan P, Bundschuh R, Killian JA, Labanowska J, Brock P, Shen R, Heerema NA, de la Chapelle A.
    Thyroid; 2018 Jun 26; 28(6):748-754. PubMed ID: 29768105
    [Abstract] [Full Text] [Related]

  • 6. BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features.
    Shi C, Cao J, Shi T, Liang M, Ding C, Lv Y, Zhang W, Li C, Gao W, Wu G, Man J.
    World J Surg Oncol; 2020 Jun 27; 18(1):145. PubMed ID: 32593310
    [Abstract] [Full Text] [Related]

  • 7. Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.
    Song JY, Sun SR, Dong F, Huang T, Wu B, Zhou J.
    Curr Med Sci; 2018 Oct 27; 38(5):785-797. PubMed ID: 30341513
    [Abstract] [Full Text] [Related]

  • 8. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, Al Kaabi J.
    PLoS One; 2020 Oct 27; 15(4):e0231341. PubMed ID: 32315324
    [Abstract] [Full Text] [Related]

  • 9. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
    Xie M, Xu ZX, Dai M, Zhu YY.
    J Coll Physicians Surg Pak; 2024 Apr 27; 34(4):445-450. PubMed ID: 38576288
    [Abstract] [Full Text] [Related]

  • 10. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
    Gao J, Ma XP, Deng FS, Jiang L, Jia WD, Li M.
    Pathol Oncol Res; 2020 Jul 27; 26(3):1833-1841. PubMed ID: 31758408
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, Accardo G, Sacco V, Bellastella A, Pannone G.
    Thyroid; 2011 Apr 27; 21(4):391-9. PubMed ID: 21385081
    [Abstract] [Full Text] [Related]

  • 12. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH, Kim IJ, Lee BJ, Lee JC, Kim IS, Kim SJ, Kim WJ, Jeon YK, Kim SS, Kim YK.
    Yonsei Med J; 2015 May 27; 56(3):634-40. PubMed ID: 25837167
    [Abstract] [Full Text] [Related]

  • 13. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb 27; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 14. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
    Kalfert D, Ludvikova M, Pesta M, Hakala T, Dostalova L, Grundmannova H, Windrichova J, Houfkova K, Knizkova T, Ludvik J, Polivka J, Kholova I.
    Pathol Res Pract; 2024 Jun 27; 258():155319. PubMed ID: 38696857
    [Abstract] [Full Text] [Related]

  • 15. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
    Yin Y, Che K, Hu J, Hua H, Dong A, Wang J, Yu J, Zhang Q, Zhao S, Zhao Y, Wang P, Wang F, Wang Y, Chi J, Sun W.
    Int J Oncol; 2020 May 27; 56(5):1284-1293. PubMed ID: 32319586
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 May 27; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 27; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 18. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
    Li R, Hao J, Zhu Z, Qiao X, Wang L, Zhou Z.
    Biomed Res Int; 2021 Feb 27; 2021():9937742. PubMed ID: 34307677
    [Abstract] [Full Text] [Related]

  • 19. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
    Lu J, Gao J, Zhang J, Sun J, Wu H, Shi X, Teng L, Liang Z.
    Int J Clin Exp Pathol; 2015 Feb 27; 8(1):793-9. PubMed ID: 25755776
    [Abstract] [Full Text] [Related]

  • 20. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M.
    World J Surg; 2016 Jul 27; 40(7):1618-24. PubMed ID: 27138882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.